The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear$115.63Fair value$366.49Bull$775.90
FairClose
52-week traded range
52W low $241.7152W high $390.34
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading close to the consensus fair value
Bio-Rad Laboratories closed at $369.32, 0.8% above the consensus fair value of $366.49 drawn from 8 valuation models.
Financial DNA score 73/100 — Strong. P/E of 13.3x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
$272.51
-26.2%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
$409.51
+10.9%
√(22.5 × EPS × BVPS)
EPS=27.85, BVPS=267.62
P/E Fair Value
$557.00
+50.8%
EPS × 20x (sector P/E)
EPS=27.85, Sector P/E=20x
Peter Lynch (PEG)
$775.90
+110.1%
EPS × Growth% (PEG = 1 is fair)
EPS=27.85, g=27.9%
EV/EBITDA
$115.63
-68.7%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=212.6M
Book Value (P/B)
$307.10
-16.8%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=267.62, ROE=10.6%, g=6%, r=10%
Reverse DCF
$369.32
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 1.6% | Historical: 27.9%
Margin of Safety
$309.76
-16.1%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=413.01, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.